Cargando…

Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice

Immunosenescence is believed to be responsible for poor vaccine efficacy in the elderly. To overcome this difficulty, research into vaccination strategies and the mechanisms of immune responses to vaccination is required. By analyzing the innate and adaptive immune responses to vaccination with vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shmeleva, Evgeniya V., Smith, Geoffrey L., Ferguson, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685358/
https://www.ncbi.nlm.nih.gov/pubmed/31417558
http://dx.doi.org/10.3389/fimmu.2019.01780
_version_ 1783442389698871296
author Shmeleva, Evgeniya V.
Smith, Geoffrey L.
Ferguson, Brian J.
author_facet Shmeleva, Evgeniya V.
Smith, Geoffrey L.
Ferguson, Brian J.
author_sort Shmeleva, Evgeniya V.
collection PubMed
description Immunosenescence is believed to be responsible for poor vaccine efficacy in the elderly. To overcome this difficulty, research into vaccination strategies and the mechanisms of immune responses to vaccination is required. By analyzing the innate and adaptive immune responses to vaccination with vaccinia virus (VACV) in mice of different age groups, we found that immune cell recruitment, production of cytokines/chemokines and control of viral replication at the site of intradermal vaccination were preserved in aged mice and were comparable with younger groups. Analysis of cervical draining lymph nodes (dLN) collected after vaccination showed that numbers of germinal center B cells and follicular T helper cells were similar across different age groups. The number of VACV-specific CD8 T cells in the spleen and the levels of serum neutralizing antibodies 1 month after vaccination were also comparable across all age groups. However, following intranasal challenge of vaccinated mice, body weight loss was lower and virus was cleared more rapidly in aged mice than in younger animals. In conclusion, vaccination with VACV can induce an effective immune response and stronger protection in elderly animals. Thus, the development of recombinant VACV-based vaccines against different infectious diseases should be considered as a strategy for improving vaccine immunogenicity and efficacy in the elderly.
format Online
Article
Text
id pubmed-6685358
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66853582019-08-15 Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice Shmeleva, Evgeniya V. Smith, Geoffrey L. Ferguson, Brian J. Front Immunol Immunology Immunosenescence is believed to be responsible for poor vaccine efficacy in the elderly. To overcome this difficulty, research into vaccination strategies and the mechanisms of immune responses to vaccination is required. By analyzing the innate and adaptive immune responses to vaccination with vaccinia virus (VACV) in mice of different age groups, we found that immune cell recruitment, production of cytokines/chemokines and control of viral replication at the site of intradermal vaccination were preserved in aged mice and were comparable with younger groups. Analysis of cervical draining lymph nodes (dLN) collected after vaccination showed that numbers of germinal center B cells and follicular T helper cells were similar across different age groups. The number of VACV-specific CD8 T cells in the spleen and the levels of serum neutralizing antibodies 1 month after vaccination were also comparable across all age groups. However, following intranasal challenge of vaccinated mice, body weight loss was lower and virus was cleared more rapidly in aged mice than in younger animals. In conclusion, vaccination with VACV can induce an effective immune response and stronger protection in elderly animals. Thus, the development of recombinant VACV-based vaccines against different infectious diseases should be considered as a strategy for improving vaccine immunogenicity and efficacy in the elderly. Frontiers Media S.A. 2019-07-31 /pmc/articles/PMC6685358/ /pubmed/31417558 http://dx.doi.org/10.3389/fimmu.2019.01780 Text en Copyright © 2019 Shmeleva, Smith and Ferguson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shmeleva, Evgeniya V.
Smith, Geoffrey L.
Ferguson, Brian J.
Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
title Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
title_full Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
title_fullStr Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
title_full_unstemmed Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
title_short Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice
title_sort enhanced efficacy of vaccination with vaccinia virus in old vs. young mice
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685358/
https://www.ncbi.nlm.nih.gov/pubmed/31417558
http://dx.doi.org/10.3389/fimmu.2019.01780
work_keys_str_mv AT shmelevaevgeniyav enhancedefficacyofvaccinationwithvacciniavirusinoldvsyoungmice
AT smithgeoffreyl enhancedefficacyofvaccinationwithvacciniavirusinoldvsyoungmice
AT fergusonbrianj enhancedefficacyofvaccinationwithvacciniavirusinoldvsyoungmice